CN Patent

CN114126580A — 用于治疗眼部过敏的眼用组合物

Assigned to Novaliq GmbH · Expires 2022-03-01 · 4y expired

What this patent protects

本发明提供了包含环孢菌素和半氟化烷烃的眼用组合物用于治疗眼部过敏和与其相关的任何症状。

USPTO Abstract

本发明提供了包含环孢菌素和半氟化烷烃的眼用组合物用于治疗眼部过敏和与其相关的任何症状。

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

Patent Metadata

Patent number: CN114126580A
Jurisdiction: CN
Classification: —
Expires: 2022-03-01
Drug substance claim: No
Drug product claim: No
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.